Implementation of an interprofessional medication adherence program for chronic patients in community pharmacies: how much does it cost for the provider?


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
08 Jan 2019
Historique:
received: 20 03 2018
accepted: 20 12 2018
entrez: 10 1 2019
pubmed: 10 1 2019
medline: 18 4 2019
Statut: epublish

Résumé

The implementation of an innovative and sustainable professional pharmacy service in routine care requires substantial resources borne by the pharmacy owner. Although a community pharmacy is a business setting, few studies have examined cost as a potential barrier to widespread implementation. Implementation costs, as the cost impact of an implementation effort, can be significant and hamper the decision to invest from the provider perspective. Traditional financial planning tools can be used to analyse and support business decision to implement a service by assessing the net impact of a new service on the provider's budget. This study aimed to estimate the implementation costs and the break-even point of an interprofessional medication adherence program for chronic patients in Switzerland. The program combines motivational interviews, medication adherence electronic monitoring and feedback reports to patient and physicians. We used a 3-step approach: (i) micro-costing analysis: identification of implementation activities, quantification and valuation of required resources. Implementation costs, including service support costs and direct delivery costs, were analysed according to the implementation phase (installation, initial implementation, and full operation); (ii) break-even analysis: estimation of the required number of patients to follow up with to ensure that the generated revenue exceeded the total cost; and (iii) univariate sensitivity analyses. The estimated total cost of the installation phase was 8481 CHF, more than half of which represented the cost of the equipment. Direct delivery costs were 666 CHF per patient per year, with 68% of this value associated with the cost of workforce time. According to the Swiss national reimbursement system, a minimal of 16 [10-27] patients was required to cover the implementation costs of the installation phase. This break-even point decreased to 13 patients in the initial and full operation phases. These estimates lead to a better understanding of the real cost of implementing a professional pharmacy service in routine care. In a Swiss context, the current medication adherence support fee-for-service system allows pharmacists to reach the break-even point. Such information is important for community pharmacists to guide their implementation strategies. The replication of similar analyses in other settings and countries is paramount.

Sections du résumé

BACKGROUND BACKGROUND
The implementation of an innovative and sustainable professional pharmacy service in routine care requires substantial resources borne by the pharmacy owner. Although a community pharmacy is a business setting, few studies have examined cost as a potential barrier to widespread implementation. Implementation costs, as the cost impact of an implementation effort, can be significant and hamper the decision to invest from the provider perspective. Traditional financial planning tools can be used to analyse and support business decision to implement a service by assessing the net impact of a new service on the provider's budget. This study aimed to estimate the implementation costs and the break-even point of an interprofessional medication adherence program for chronic patients in Switzerland. The program combines motivational interviews, medication adherence electronic monitoring and feedback reports to patient and physicians.
METHODS METHODS
We used a 3-step approach: (i) micro-costing analysis: identification of implementation activities, quantification and valuation of required resources. Implementation costs, including service support costs and direct delivery costs, were analysed according to the implementation phase (installation, initial implementation, and full operation); (ii) break-even analysis: estimation of the required number of patients to follow up with to ensure that the generated revenue exceeded the total cost; and (iii) univariate sensitivity analyses.
RESULTS RESULTS
The estimated total cost of the installation phase was 8481 CHF, more than half of which represented the cost of the equipment. Direct delivery costs were 666 CHF per patient per year, with 68% of this value associated with the cost of workforce time. According to the Swiss national reimbursement system, a minimal of 16 [10-27] patients was required to cover the implementation costs of the installation phase. This break-even point decreased to 13 patients in the initial and full operation phases.
CONCLUSIONS CONCLUSIONS
These estimates lead to a better understanding of the real cost of implementing a professional pharmacy service in routine care. In a Swiss context, the current medication adherence support fee-for-service system allows pharmacists to reach the break-even point. Such information is important for community pharmacists to guide their implementation strategies. The replication of similar analyses in other settings and countries is paramount.

Identifiants

pubmed: 30621697
doi: 10.1186/s12913-018-3851-x
pii: 10.1186/s12913-018-3851-x
pmc: PMC6323833
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15

Références

J Stud Alcohol Drugs. 2015 Mar;76(2):222-8
pubmed: 25785797
AIDS Care. 2011 May;23(5):550-61
pubmed: 21271406
Cochrane Database Syst Rev. 2010 Jul 07;(7):CD000336
pubmed: 20614422
Pharmacoepidemiol Drug Saf. 2015 Oct;24(10):1105-13
pubmed: 25903307
Int J Clin Pharm. 2017 Aug;39(4):750-758
pubmed: 28434119
Eval Health Prof. 2006 Sep;29(3):334-47
pubmed: 16868341
Nurs Econ. 2005 Jan-Feb;23(1):31-4, 3
pubmed: 15768782
Cochrane Database Syst Rev. 2014 Nov 20;(11):CD000011
pubmed: 25412402
Adm Policy Ment Health. 2011 Mar;38(2):65-76
pubmed: 20957426
Pharm World Sci. 2006 Apr;28(2):65-72
pubmed: 16791717
Pharm Pract (Granada). 2012 Jul;10(3):151-8
pubmed: 24155831
Int J Clin Pharm. 2014 Oct;36(5):1014-22
pubmed: 25139136
Health Policy. 2016 Dec;120(12):1350-1362
pubmed: 28228230
J Am Coll Cardiol. 2016 Jun 21;67(24):2846-54
pubmed: 27058907
Child Youth Serv Rev. 2014 Apr 1;39:177-182
pubmed: 24729650
AIDS. 2015 Oct 23;29(16):2195-200
pubmed: 26544582
J Clin Pharm Ther. 2011 Oct;36(5):602-13
pubmed: 21143256
Biomed Res Int. 2015;2015:103546
pubmed: 26839879
Health Serv Res. 2009 Feb;44(1):225-44
pubmed: 19146566
Health Policy. 2008 Dec;88(2-3):258-68
pubmed: 18468713
Lancet Infect Dis. 2017 Jun;17(6):595-604
pubmed: 28262598
Pharmacoeconomics. 2013 Dec;31(12):1155-68
pubmed: 24222477
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Patient Prefer Adherence. 2013 Dec 05;8:1-13
pubmed: 24353407
Can Pharm J (Ott). 2014 Jul;147(4):209-32
pubmed: 25360148
Med Care Res Rev. 2013 Jun;70(3):235-66
pubmed: 23035056
Int J Pharm Pract. 2015 Aug;23(4):237-247
pubmed: 25377218
Pharm World Sci. 2010 Dec;32(6):776-86
pubmed: 20862544
Pharm Pract (Granada). 2010 Jan;8(1):35-42
pubmed: 25152791
Res Social Adm Pharm. 2017 May - Jun;13(3):614-627
pubmed: 27423785
Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa323
pubmed: 32913876
Ann Pharmacother. 2008 Jun;42(6):861-8
pubmed: 18477730

Auteurs

Clemence Perraudin (C)

Department of Ambulatory Care and Community Medicine, Community Pharmacy Center, University of Lausanne, Lausanne, Switzerland. Clemence.perraudin@hospvd.ch.

Jean-François Locca (JF)

Pharmacie de Prilly, Community Pharmacy, Prilly, Switzerland.

Christophe Rossier (C)

Pharmacie de l'Ile, Community Pharmacy, Rolle, Switzerland.

Olivier Bugnon (O)

Department of Ambulatory Care and Community Medicine, Community Pharmacy Center, University of Lausanne, Lausanne, Switzerland.
Community Pharmacy Practice Research, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.

Marie-Paule Schneider (MP)

Department of Ambulatory Care and Community Medicine, Community Pharmacy Center, University of Lausanne, Lausanne, Switzerland.
Community Pharmacy Practice Research, School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH